DOCSLIB.ORG

Integrated Molecular Profiling for Analyzing and Predicting Therapeutic Mechanism, Response, Biomarker and Target

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Integrated Molecular Profiling for Analyzing and Predicting Therapeutic Mechanism, Response, Biomarker and Target INTEGRATED MOLECULAR PROFILING FOR ANALYZING AND PREDICTING THERAPEUTIC MECHANISM, RESPONSE, BIOMARKER AND TARGET Jia Jia (B. Sci & M. Sci, Zhejiang University) A THESIS SUBMITTED FOR THE DEGREE OF DOCTOR OF PHILOSOPHY DEPARTMENT OF PHARMACY NATIONAL UNIVERSITY OF SINGAPORE 2010 Acknowledgements ACKNOWLEDGEMENTS I would like to deeply thank Professor Chen Yu Zong, for his constant encouragement and advice during the entire period of my postgraduate studies. In particular, he has guided me to make my research applicable to the real world problem. This work would not have been possible without his kindness in supporting me to shape up the manuscript for publication. I am also tremendously benefited from his profound knowledge, expertise in scientific research, as well as his enormous support, which will inspire and motivate me to go further in my future professional career. I am also grateful to our BIDD group members for their insight suggestions and collaborations in my research work: Dr. Tang Zhiqun, Ms. Ma Xiaohua, Mr. Zhu Feng, Ms. Liu Xin, Ms. Shi Zhe, Dr. Cui Juan, Mr. Tu Weimin, Dr. Zhang Hailei, Dr. Lin Honghuang, Dr. Liu Xianghui, Dr. Pankaj Kumar, Dr Yap Chun wei, Ms. Wei Xiaona, Ms. Huang Lu, Mr. Zhang Jinxian, Mr. Han Bucong, Mr. Tao Lin, Dr. Wang Rong, Dr. Yan Kun. I thank them for their valuable support and encouragement in my work. Finally, I owe my gratitude to my parents for their forever love, constant support, understanding, encouragement and strength throughout my life. A special appreciation goes to all for love and support. Jia Jia August 2010 I Table of Contents TABLE OF CONTENTS 1.1 Overview of mechanism and strategies of molecular-targeted therapeutics .................................... 2 1.1.1 Current progress of molecular-targeted cancer therapeutics ..................................................... 3 1.1.2 Challenges of targeted cancer therapy, receptor tyrosine kinase as a case study ...................... 5 1.1.3 Systematic discovery of multicomponent therapies .................................................................. 7 1.2 Current progress in cancer biomarker discovery ............................................................................ 14 1.2.1 Introduction to biomarker in cancer diagnosis and prediction ................................................ 14 1.2.2 Types of cancer biomakers ...................................................................................................... 15 1.2.3 Approaches of cancer biomarker discovery ............................................................................ 16 1.2.4 Brief introduction of microarray technology ........................................................................... 20 1.2.5 The problems of current marker selection methods ................................................................ 29 1.3 Current progress in tumor antigen discovery ................................................................................. 31 1.3.1 Overview of tumor vaccine for cancer immunotherapy .......................................................... 31 1.3.2 Introduction toT cell-defined tumor antigens .......................................................................... 36 1.3.3 Application of computational methods for MHC-binding peptides and epitopes prediction .. 39 1.4 Scope and research objective ........................................................................................................... 41 2.1 Introduction to machine learning methods..................................................................................... 45 2.1.1 Support Vector Machines ........................................................................................................ 47 2.1.2 Probabilistic neural network ................................................................................................... 51 2.1.3 Hierarchical clustering ............................................................................................................ 53 2.1.4 Parameters optimization and model validation ....................................................................... 55 2.1.5 Performance evaluation ........................................................................................................... 56 2.2 Methodology for microarray data processing ................................................................................. 58 2.2.1 Preprocessing of microarray data ............................................................................................ 58 2.2.2 Normalization and scaling ....................................................................................................... 59 2.2.3 Threshold filtering ................................................................................................................... 61 2.2.4 Missing data estimation........................................................................................................... 62 2.3 Feature selection procedure ............................................................................................................ 63 2.3.1 REF based gene selection procedure ....................................................................................... 64 2.3.2 Recursive feature elimination ................................................................................................. 66 2.3.3 Random sampling, feature elimination and consistency evaluation ........................................ 67 2.4 Construction of the feature vector for peptide ................................................................................ 69 2.4.1 Feature vector for peptide ....................................................................................................... 69 2.4.2 Scaling of feature vector ......................................................................................................... 70 3.1 Introduction ..................................................................................................................................... 74 3.2 Materials and Methods .................................................................................................................... 77 3.2.1 Mechanism of drug interactions .............................................................................................. 77 3.2.2 Methods for drug-combination analysis .................................................................................. 78 3.2.3 Collection of literature-reported drug combinations ............................................................... 78 3.3 Results and discussion ..................................................................................................................... 79 3.3.1 Statistics of collected drug combinations and MI profiles ...................................................... 79 3.3.2 Mechanism underlying the pharmacokinetic and pharmacodynamic drug interactions .......... 80 3.4 Conclusion ..................................................................................................................................... 102 4.1 Introduction ................................................................................................................................... 107 4.2 Materials and Methods .................................................................................................................. 109 4.2.1 Data collection and preprocessing......................................................................................... 109 4.2.2 Bypass mechanism of studied tyrosin kinase inhibitors ........................................................ 116 4.2.3 Drug sensitivity evaluation procedure ................................................................................... 116 4.3 Results and discussion ................................................................................................................... 119 II Table of Contents 4.3.1 Assesment of EGFR-I sensitivity prediction by mutation and amplification profiles ........... 119 4.3.2 Assessment of integrated molecular profiling for predicting TKIs sensitivity ...................... 121 4.3.3 The distribution and coexistence of drug sensitive and resistant profiles ............................. 122 4.4 Summary ........................................................................................................................................ 132 5.1 Introduction ................................................................................................................................... 133 5.2 Materials and Methods .................................................................................................................. 136 5.2.1 Collection of genomic, mutation and expression data ........................................................... 136 5.2.2 Collection of tumor-specific antigen ..................................................................................... 136 5.2.3 Computational procedures .................................................................................................... 137 5.3 Results and Discussion .................................................................................................................. 142 5.3.1 Performance of collective approach in genome-scaled TSAs identification ......................... 142 5.4 Conclusion ..................................................................................................................................... 144 6.1 Introduction ..................................................................................................................................
Load more

Recommended publications
  • Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications
    International Journal of Molecular Sciences Review Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications Daniel Fernández-Villa 1, Maria Rosa Aguilar 1,2 and Luis Rojo 1,2,* 1 Instituto de Ciencia y Tecnología de Polímeros, Consejo Superior de Investigaciones Científicas, CSIC, 28006 Madrid, Spain; [email protected] (D.F.-V.); [email protected] (M.R.A.) 2 Consorcio Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, 28029 Madrid, Spain * Correspondence: [email protected]; Tel.: +34-915-622-900 Received: 18 September 2019; Accepted: 7 October 2019; Published: 9 October 2019 Abstract: Bacterial, protozoan and other microbial infections share an accelerated metabolic rate. In order to ensure a proper functioning of cell replication and proteins and nucleic acids synthesis processes, folate metabolism rate is also increased in these cases. For this reason, folic acid antagonists have been used since their discovery to treat different kinds of microbial infections, taking advantage of this metabolic difference when compared with human cells. However, resistances to these compounds have emerged since then and only combined therapies are currently used in clinic. In addition, some of these compounds have been found to have an immunomodulatory behavior that allows clinicians using them as anti-inflammatory or immunosuppressive drugs. Therefore, the aim of this review is to provide an updated state-of-the-art on the use of antifolates as antibacterial and immunomodulating agents in the clinical setting, as well as to present their action mechanisms and currently investigated biomedical applications. Keywords: folic acid antagonists; antifolates; antibiotics; antibacterials; immunomodulation; sulfonamides; antimalarial 1.
    [Show full text]
  • Discovery of Anti-Amoebic Inhibitors from Screening the MMV Pandemic Response Box on Balamuthia Mandrillaris, Naegleria Fowleri
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.14.096776; this version posted May 15, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Article 2 Discovery of anti-amoebic inhibitors from screening 3 the MMV Pandemic Response Box on Balamuthia 4 mandrillaris, Naegleria fowleri and Acanthamoeba 5 castellanii 6 Christopher A. Rice1,2,Δ,†,*, Emma V. Troth2,3,†, A. Cassiopeia Russell2,3,†, and Dennis E. Kyle1,2,3,* 7 1 Department of Cellular Biology, University of Georgia, Athens, Georgia, USA. 8 2 Center for Tropical and Emerging Global Diseases, Athens, Georgia, USA. 9 3 Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA. 10 Δ Current address: Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, 11 University of Georgia, Athens, Georgia, USA. 12 † These authors contributed equally to this work. 13 14 *Author correspondence: [email protected] (D.E.K) and [email protected] (C.A.R) 15 Received: date; Accepted: date; Published: date 16 Abstract: Pathogenic free-living amoebae, Balamuthia mandrillaris, Naegleria fowleri and several 17 Acanthamoeba species are the etiological agents of severe brain diseases, with case mortality rates 18 >90%. A number of constraints including misdiagnosis and partially effective treatments lead to 19 these high fatality rates. The unmet medical need is for rapidly acting, highly potent new drugs to 20 reduce these alarming mortality rates. Herein, we report the discovery of new drugs as potential 21 anti-amoebic agents.
    [Show full text]
  • 1,4-Disubstituted-1,2,3-Triazole Compounds Induce Ultrastructural Alterations in Leishmania Amazonensis Promastigote
    International Journal of Molecular Sciences Article 1,4-Disubstituted-1,2,3-Triazole Compounds Induce Ultrastructural Alterations in Leishmania amazonensis Promastigote: An in Vitro Antileishmanial and in Silico Pharmacokinetic Study Fernando Almeida-Souza 1,2,* , Verônica Diniz da Silva 3,4, Gabriel Xavier Silva 5, Noemi Nosomi Taniwaki 6, Daiana de Jesus Hardoim 2, Camilla Djenne Buarque 3, 1, , 2, Ana Lucia Abreu-Silva * y and Kátia da Silva Calabrese y 1 Pós-graduação em Ciência Animal, Universidade Estadual do Maranhão, São Luís 65055-310, Brazil 2 Laboratório de Imunomodulação e Protozoologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro 21040-900, Brazil; [email protected] (D.d.J.H.); calabrese@ioc.fiocruz.br (K.d.S.C.) 3 Laboratório de Síntese Orgânica, Pontifícia Universidade Católica, Rio de Janeiro 22451-900, Brazil; [email protected] (V.D.d.S.); [email protected] (C.D.B.) 4 Faculdade de Ciência e Tecnologia, Universidade Nova de Lisboa, 2825-149 Caparica, Portugal 5 Rede Nordeste de Biotecnologia, Universidade Federal do Maranhão, São Luís 65080-805, Brazil; [email protected] 6 Núcleo de Microscopia Eletrônica, Instituto Adolfo Lutz, São Paulo 01246-000, Brazil; [email protected] * Correspondence: [email protected] (F.A.-S.); [email protected] (A.L.A.-S.) These authors equally contributed to this work. y Received: 26 June 2020; Accepted: 14 July 2020; Published: 18 September 2020 Abstract: The current standard treatment for leishmaniasis has remained the same for over 100 years, despite inducing several adverse effects and increasing cases of resistance. In this study we evaluated the in vitro antileishmanial activity of 1,4-disubstituted-1,2,3 triazole compounds and carried out in silico predictive study of their pharmacokinetic and toxicity properties.
    [Show full text]
  • Review Article Sporotrichosis: an Overview and Therapeutic Options
    Hindawi Publishing Corporation Dermatology Research and Practice Volume 2014, Article ID 272376, 13 pages http://dx.doi.org/10.1155/2014/272376 Review Article Sporotrichosis: An Overview and Therapeutic Options Vikram K. Mahajan Department of Dermatology, Venereology & Leprosy, Dr. R. P. Govt. Medical College, Kangra, Tanda, Himachal Pradesh 176001, India Correspondence should be addressed to Vikram K. Mahajan; [email protected] Received 30 July 2014; Accepted 12 December 2014; Published 29 December 2014 Academic Editor: Craig G. Burkhart Copyright © 2014 Vikram K. Mahajan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Sporotrichosis is a chronic granulomatous mycotic infection caused by Sporothrix schenckii, a common saprophyte of soil, decaying wood, hay, and sphagnum moss, that is endemic in tropical/subtropical areas. The recent phylogenetic studies have delineated the geographic distribution of multiple distinct Sporothrix species causing sporotrichosis. It characteristically involves the skin and subcutaneous tissue following traumatic inoculation of the pathogen. After a variable incubation period, progressively enlarging papulo-nodule at the inoculation site develops that may ulcerate (fixed cutaneous sporotrichosis) or multiple nodules appear proximally along lymphatics (lymphocutaneous sporotrichosis). Osteoarticular sporotrichosis or primary pulmonary sporotrichosis are rare and occur from direct inoculation or inhalation of conidia, respectively. Disseminated cutaneous sporotrichosis or involvement of multiple visceral organs, particularly the central nervous system, occurs most commonly in persons with immunosuppression. Saturated solution of potassium iodide remains a first line treatment choice for uncomplicated cutaneous sporotrichosis in resource poor countries but itraconazole is currently used/recommended for the treatment of all forms of sporotrichosis.
    [Show full text]
  • Generate Metabolic Map Poster
    Authors: Pallavi Subhraveti Anamika Kothari Quang Ong Ron Caspi An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Ingrid Keseler Peter D Karp Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Csac1394711Cyc: Candidatus Saccharibacteria bacterium RAAC3_TM7_1 Cellular Overview Connections between pathways are omitted for legibility. Tim Holland TM7C00001G0420 TM7C00001G0109 TM7C00001G0953 TM7C00001G0666 TM7C00001G0203 TM7C00001G0886 TM7C00001G0113 TM7C00001G0247 TM7C00001G0735 TM7C00001G0001 TM7C00001G0509 TM7C00001G0264 TM7C00001G0176 TM7C00001G0342 TM7C00001G0055 TM7C00001G0120 TM7C00001G0642 TM7C00001G0837 TM7C00001G0101 TM7C00001G0559 TM7C00001G0810 TM7C00001G0656 TM7C00001G0180 TM7C00001G0742 TM7C00001G0128 TM7C00001G0831 TM7C00001G0517 TM7C00001G0238 TM7C00001G0079 TM7C00001G0111 TM7C00001G0961 TM7C00001G0743 TM7C00001G0893 TM7C00001G0630 TM7C00001G0360 TM7C00001G0616 TM7C00001G0162 TM7C00001G0006 TM7C00001G0365 TM7C00001G0596 TM7C00001G0141 TM7C00001G0689 TM7C00001G0273 TM7C00001G0126 TM7C00001G0717 TM7C00001G0110 TM7C00001G0278 TM7C00001G0734 TM7C00001G0444 TM7C00001G0019 TM7C00001G0381 TM7C00001G0874 TM7C00001G0318 TM7C00001G0451 TM7C00001G0306 TM7C00001G0928 TM7C00001G0622 TM7C00001G0150 TM7C00001G0439 TM7C00001G0233 TM7C00001G0462 TM7C00001G0421 TM7C00001G0220 TM7C00001G0276 TM7C00001G0054 TM7C00001G0419 TM7C00001G0252 TM7C00001G0592 TM7C00001G0628 TM7C00001G0200 TM7C00001G0709 TM7C00001G0025 TM7C00001G0846 TM7C00001G0163 TM7C00001G0142 TM7C00001G0895 TM7C00001G0930 Detoxification Carbohydrate Biosynthesis DNA combined with a 2'- di-trans,octa-cis a 2'- Amino Acid Degradation an L-methionyl- TM7C00001G0190 superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis (E.
    [Show full text]
  • Coordinated Slowing of Metabolism in Enteric Bacteria Under Nitrogen
    Coordinated Slowing of Metabolism in Enteric Bacteria under Nitrogen Limitation: A Perspective Ned S. Wingreen NEC Research Institute, 4 Independence Way Princeton, New Jersey 08540 and Department of Physics, University of California Berkeley, CA 94720 Sydney Kustu Department of Plant Biology, Molecular and Cell Biology University of California, Berkeley, CA 94720 Abstract It is natural to ask how bacteria coordinate metabolism when depletion of an essential nutrient limits their growth, and they must slow their entire rate of biosyn- thesis. A major nutrient with a fluctuating abundance is nitrogen. The growth rate of enteric bacteria under nitrogen-limiting conditions is known to correlate with the internal concentration of free glutamine, the glutamine pool. Here we compare the patterns of utilization of L-glutamine and L-glutamate, the two central inter- mediates of nitrogen metabolism. Monomeric precursors of all of the cell’s macro- molecules – proteins, nucleic acids, and surface polymers – require the amide group of glutamine at the first dedicated step of biosynthesis. This is the case even though only a minority (∼12%) of total cell nitrogen derives from glutamine. In contrast, the amino group of glutamate, which provides the remainder of cell nitrogen, is arXiv:physics/0110037v1 [physics.bio-ph] 12 Oct 2001 generally required late in biosynthetic pathways, e.g. in transaminase reactions for amino acid synthesis. We propose that the pattern of glutamine dependence coor- dinates the decrease in biosynthesis under conditions of nitrogen limitation. Hence, the glutamine pool plays a global regulatory role in the cell. 1 INTRODUCTION Enteric bacteria are notable for their varying environment.
    [Show full text]
  • 2011/058582 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date i 1 m 19 May 2011 (19.05.2011) 2011/058582 Al (51) International Patent Classification: Road, Sholinganallur, Chennai 600 119 (IN). CHEN- C07C 259/06 (2006.01) A61P 31/00 (2006.01) NIAPPAN, Vinoth Kumar [IN/IN]; Orchid Research C07D 277/46 (2006.01) A61K 31/426 (2006.01) Laboratories Ltd., R & D Centre: Plot No: 476/14, Old C07D 277/48 (2006.01) A61K 31/55 (2006.01) Mahabalipuram Road, Sholinganallur, Chennai 600 119 C07D 487/08 (2006.01) (IN). GANESAN, Karthikeyan [IN/IN]; Orchid Re search Laboratories Ltd., R & D Centre: Plot No: 476/14, (21) International Application Number: Old Mahabalipuram Road, Sholinganallur, Chennai 600 PCT/IN20 10/000738 119 (IN). NARAYANAN, Shridhar [IN/IN]; Orchid Re (22) International Filing Date: search Laboratories Ltd., R & D Centre: Plot No: 476/14, 12 November 2010 (12.1 1.2010) Old Mahabalipuram Road, Sholinganallur, Chennai 600 119 (IN). (25) Filing Language: English (74) Agent: UDAYAMPALAYAM PALANISAMY, (26) Publication Language: English Senthilkumar; Orchid Chemicals & Pharmaceuticals (30) Priority Data: LTD., R & D Centre: Plot No: 476/14, Old Mahabalipu 2810/CHE/2009 16 November 2009 (16. 11.2009) IN ram Road, Sholinganallur, Chennai 600 119 (IN). (71) Applicant (for all designated States except US): OR¬ (81) Designated States (unless otherwise indicated, for every CHID RESEARCH LABORATORIES LTD. [IN/IN]; kind of national protection available): AE, AG, AL, AM, Orchid Towers, 313, Valluvar Kottam High Road, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, Nungambakkam, Chennai 600 034 (IN).
    [Show full text]
  • DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents
    molecules Review DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents Maria Valeria Raimondi 1,*,† , Ornella Randazzo 1,†, Mery La Franca 1 , Giampaolo Barone 1 , Elisa Vignoni 2, Daniela Rossi 2 and Simona Collina 2,* 1 Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, via Archirafi 32, 90123 Palermo, Italy; [email protected] (O.R.); [email protected] (M.L.F.); [email protected] (G.B.) 2 Drug Sciences Department, Medicinal Chemistry and Pharmaceutical Technology Section, University of Pavia, via Taramelli 12, 27100 Pavia, Italy; [email protected] (E.V.); [email protected] (D.R.) * Correspondence: [email protected] (M.V.R.); [email protected] (S.C.); Tel.: +390-912-389-1915 (M.V.R.); +390-382-987-379 (S.C.) † These Authors contributed equally to this work. Academic Editors: Simona Collina and Mariarosaria Miloso Received: 25 February 2019; Accepted: 20 March 2019; Published: 22 March 2019 Abstract: Dihydrofolate reductase inhibitors are an important class of drugs, as evidenced by their use as antibacterial, antimalarial, antifungal, and anticancer agents. Progress in understanding the biochemical basis of mechanisms responsible for enzyme selectivity and antiproliferative effects has renewed the interest in antifolates for cancer chemotherapy and prompted the medicinal chemistry community to develop novel and selective human DHFR inhibitors, thus leading to a new generation of DHFR inhibitors. This work summarizes the mechanism of action, chemical, and anticancer profile of the DHFR inhibitors discovered in the last six years. New strategies in DHFR drug discovery are also provided, in order to thoroughly delineate the current landscape for medicinal chemists interested in furthering this study in the anticancer field.
    [Show full text]
  • Abstract #15 Drug Repurposing for Human Visceral Leishmaniasis: Screening Marketed Antifungal Azoles for Inhibition of Leishmani
    Abstract #15 Drug Repurposing for Human Visceral Leishmaniasis: Screening Marketed Antifungal Azoles for Inhibition of Leishmanial CYP5122A1 and CYP51 Enzymes Yiru Jin1, Mei Feng1, Michael Zhuo Wang1 1Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA CYP5122A1 is a novel cytochrome P450 (CYP) enzyme that is essential for the survival of Leishmania donovani, a major causative agent for human visceral leishmaniasis. Recent studies suggest that CYP5122A1 plays an important role as sterol 4-demethylase in ergosterol biosynthesis by Leishmania. Thus, CYP5122A1 inhibitors may represent a new therapeutic approach against the devastating infectious disease. To evaluate the effects of antifungal azoles on CYP5122A1, a panel of twenty marketed antifungal azoles (bifonazole, butoconazole, clotrimazole, econazole, efinaconazole, fenticonazole, fluconazole, isavuconazole, isoconazole, itraconazole, ketoconazole, miconazole, oxiconazole, posaconazole, ravuconazole, sertaconazole, sulconazole, terconazole, tioconazole, voriconazole) were screened for inhibition of CYP5122A1, as well as the lanosterol 14α-demethylase CYP51, using a fluorescence-based inhibition assay. All twenty azoles were potent inhibitors of leishmanial CYP51 with IC50 ranging from 0.031 to 0.084 M, whereas their inhibitory potencies against CYP5122A1 were much lower (0.25 to 12 M). Ravuconazole was identified as a selective CYP51 inhibitor with an IC50 value of 0.048 M and selectivity index of 250 against CYP5122A1. Interestingly, the imidazole class of antifungal azoles showed stronger inhibition against CYP5122A1 compared with the triazole class. These results can provide insights toward rational drug design of CYP5122A1 inhibitors. Future studies will attempt to obtain X-ray crystal structures of several select protein-ligand complexes and confirm the proposed biochemical roles of CYP5122A1 and CYP51 by treating parasites with selective inhibitors, followed by HPLC-MS/MS-based sterol analysis.
    [Show full text]
  • Metabolic Characterization of Folate Precursor Paba Uncovers Its Folate Independent Activity on Root Growth of Arabidopsis Thaliana
    Inaugural-Dissertation zur Erlangung der Doktorwürde der Albert-Ludwigs-Universität Freiburg im Breisgau Metabolic characterization of folate precursor pABA uncovers its folate independent activity on root growth of Arabidopsis thaliana . Philip Kochersperger Institut für Biologie II (Botanik) September 2011 Dekan: Prof. Dr. Gunther Neuhaus Promotionsvorsitzender: Prof. Dr. Samuel Rossel Betreuer der Arbeit: Prof. Dr. Klaus Palme und Dr. Franck Ditengou Kogutachter: Prof. Dr. Thomas Laux Drittprüfer: Prof. Dr. Ralf Reski Tag der Verkündigung des Prüfungsergebnisses: 04.05.2012 2 I Table of contents I Table of contents ...................................................................................................... 3 II Figure index ............................................................................................................. 6 III Table index ............................................................................................................. 6 IV Abbreviations ......................................................................................................... 7 V Zusammenfassung auf Deutsch ............................................................................ 11 1 Introduction ............................................................................................................ 12 1.1 Abstract ........................................................................................................... 12 1.2 Folates are essential cofactors for almost all living organisms .......................
    [Show full text]
  • PRT6/At5g02310 Encodes an Arabidopsis Ubiquitin Ligase of the N-End Rule Pathway with Arginine Specificity and Is Not the CER3 Locus
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector FEBS Letters 581 (2007) 3189–3196 PRT6/At5g02310 encodes an Arabidopsis ubiquitin ligase of the N-end rule pathway with arginine specificity and is not the CER3 locus Marcus Garzo´na, Karolin Eiflera, Andrea Faustb, Hartmut Scheelc, Kay Hofmannc, Csaba Koncza, Alexander Yephremovb, Andreas Bachmaira,* a Department of Plant Developmental Biology, Max Planck Institute for Plant Breeding Research, Carl-von-Linne´-Weg 10, D-50829 Cologne, Germany b Department of Molecular Plant Genetics, Max Planck Institute for Plant Breeding Research, Carl-von-Linne´-Weg 10, D-50829 Cologne, Germany c Bioinformatics Group, Miltenyi Biotec GmbH, Stockheimer Weg 1, D-50829 Cologne, Germany Received 10 May 2007; revised 4 June 2007; accepted 5 June 2007 Available online 12 June 2007 Edited by Ulf-Ingo Flu¨gge mini of cellular proteins, do not target these proteins for deg- Abstract The eukaryotic N-end rule pathway mediates ubiqui- tin- and proteasome-dependent turnover of proteins with a bulky radation. Substrates of the eukaryotic N-end rule pathway amino-terminal residue. Arabidopsis locus At5g02310 shows sig- include components of NO signaling in animals [11], and pro- nificant similarity to the yeast N-end rule ligase Ubr1. We dem- teins important for pathogen defense and senescence in plants onstrate that At5g02310 is a ubiquitin ligase and mediates [12,13]. degradation of proteins with amino-terminal Arg residue. Unlike Saccharomyces cerevisiae was found to have a single ubiqui- Ubr1, the Arabidopsis protein does not participate in degrada- tin ligase devoted to the N-end rule, termed Ubr1 [14], whereas tion of proteins with amino-terminal Phe or Leu.
    [Show full text]
  • Regulation of Translation by One-Carbon Metabolism in Bacteria
    REVIEWS Regulation of translation by one-carbon metabolism in bacteria and eukaryotic organelles Received for publication, May 12, 2020, and in revised form, November 15, 2020 Published, Papers in Press, November 16, 2020, https://doi.org/10.1074/jbc.REV120.011985 Sunil Shetty1 and Umesh Varshney2,3,* From the 1Biozentrum, University of Basel, Basel, Switzerland; 2Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India; 3Jawaharlal Nehru Centre for Advanced Scientific Studies, Jakkur, Bangalore, India Edited by Karin Musier-Forsyth Protein synthesis is an energetically costly cellular activity. It also employed as antibiotics. The sulfonamides (sulfa drugs) is therefore important that the process of mRNA translation such as sulfachloropyridazine (SCP) and sulfamethoxazole remains in excellent synchrony with cellular metabolism and its (SMX) and trimethoprim (TMP) are perhaps the most promi- energy reserves. Unregulated translation could lead to the pro- nent examples of OCM inhibitors (3). Interestingly, treatment of duction of incomplete, mistranslated, or misfolded proteins, Escherichia coli with TMP inhibited translation within 15 min squandering the energy needed for cellular sustenance and (4). Supplementation of the growth media with the products of causing cytotoxicity. One-carbon metabolism (OCM), an inte- OCM such as methionine, purines, and thymidine could not gral part of cellular intermediary metabolism, produces a num- rescue translation in the presence of TMP, indicating a direct ber of one-carbon unit intermediates (formyl, methylene, contribution of OCM in translation (5, 6). Unfortunately, methenyl, methyl). These OCM intermediates are required for resistance to sulfa drugs arose rapidly (7). However, recent the production of amino acids such as methionine and other studies have shown that OCM inhibitors could serve as effective biomolecules such as purines, thymidylate, and redox regulators.
    [Show full text]